What does a normal angiogram mean?

A normal (or non-obstructive) coronary angiogram means that no coronary artery has a stenosis above 50%, the threshold for obstructive disease. It does not mean no coronary disease, no ischemia, and no cardiac cause of chest pain. It means the test did not find obstructive plaque. The causes of chest pain that a standard angiogram cannot detect include microvascular coronary dysfunction, coronary vasospasm, SCAD (if mild), and non-obstructive plaque. All of these can cause real chest pain, real ischemia, and real cardiovascular events.

ANOCA stands for Angina with Non-Obstructive Coronary Arteries. It is the stable angina counterpart to MINOCA (the acute MI version of the same finding). ANOCA patients have exertional or rest chest pain that is ischemic in character, pressure, heaviness, radiating to the jaw or arm, with angiography showing no culprit obstructive stenosis. Approximately 50-60% of ANOCA patients have microvascular coronary dysfunction detectable on further testing. ANOCA is approximately 2:1 female.

What is microvascular coronary dysfunction and how does it cause chest pain?

Microvascular coronary dysfunction (MCD) is impaired function of the small coronary arterioles, the vessels too small to be seen on standard angiography. In MCD, these small vessels either fail to dilate normally in response to increased myocardial demand (impaired coronary flow reserve) or constrict abnormally. The result is true myocardial ischemia, reduced blood flow and oxygen delivery to the heart muscle, that produces real chest pain and can cause ECG changes, even though the large coronary arteries look clean. MCD is more common in women and is linked to estrogen loss, inflammation, and metabolic syndrome.

What additional testing diagnoses the cause of chest pain after a normal angiogram?

Coronary physiology testing during catheterization, specifically coronary flow reserve (CFR) measurement and microvascular resistance index, identifies microvascular dysfunction in the majority of ANOCA cases when performed. Intracoronary acetylcholine provocation testing diagnoses coronary vasospasm by triggering a controlled spasm during catheterization. Cardiac MRI (CMR) with stress perfusion can detect stress-induced ischemia in the absence of obstructive disease. These tests are significantly underperformed in the United States, particularly in women.

What is the prognosis of ANOCA and microvascular angina?

ANOCA and MCD are not benign findings. Women with ANOCA have higher rates of major adverse cardiovascular events (MACE) than age-matched women without cardiac symptoms, approximately 2-fold over 5 years. The Women's Ischemia Syndrome Evaluation (WISE) study demonstrated that women with MCD have elevated cardiovascular event rates, impaired quality of life, and higher rates of cardiac hospitalization than previously recognized. This is not a reassuring diagnosis.

The Unseen Coronary

Your Angiogram Was Normal. You Are Not Fine. Here Is What the Test Cannot See.

A normal angiogram means no obstructive plaque above 50%. It does not mean no coronary disease. For women with ongoing chest pain, here is what the test misses.

Job Mogire, MD, FACP, FACC · Medically reviewed June 16, 2026

She had been having chest pain for two years. Pressure behind her sternum, into her jaw and left arm, brought on by climbing stairs or walking fast and sometimes coming on at rest. She had seen three physicians. They had each ordered an ECG, which was normal. At her insistence, a cardiologist performed a coronary angiogram. The report came back: non-obstructive coronary arteries, no culprit stenosis. She was told the heart looks fine. She continued having chest pain.

The Mechanism

Standard coronary angiography images the epicardial coronary arteries, the large vessels that run along the surface of the heart and branch into progressively smaller vessels. It detects narrowing that is severe enough to restrict blood flow through those large vessels. It does not image, and cannot evaluate, three categories of disease that cause real ischemia in women.

The microvasculature. The small coronary arterioles, vessels 150 to 300 microns in diameter that distribute blood into the myocardium itself, are invisible on standard angiography. Their function cannot be assessed by anatomic imaging. They require physiological testing: coronary flow reserve measurement and microvascular resistance indices obtained during catheterization, or stress perfusion imaging on cardiac MRI. When these vessels fail to dilate in response to increased cardiac demand, the myocardium is genuinely underperfused. True ischemia, measurable by lactate production, ST-segment shifts, and wall motion abnormality, occurs at a level of coronary anatomy the angiogram cannot resolve.

Vasospasm that has resolved. Coronary vasospasm is transient focal constriction of a coronary artery, real and significant constriction that restricts blood flow and causes ischemia, that resolves completely within minutes. A standard angiogram performed after the spasm has passed shows a completely normal artery. The physiology is established: acetylcholine and other stimuli activate muscarinic receptors on smooth muscle cells, triggering calcium influx and contraction. In patients prone to vasospasm, endothelial dysfunction impairs the nitric oxide counter-signal that normally prevents excessive smooth muscle constriction. The spasm occurs, produces symptoms and ECG changes, then resolves. The test arrives too late. Approximately 20 to 30 percent of ANOCA patients demonstrate coronary vasospasm on provocative testing during catheterization, according to data from the CorMicA trial and European registry series.

Non-obstructive plaque and plaque erosion. Plaque that does not narrow the lumen beyond 50 percent does not register as a stenosis on the angiogram report. Yet non-obstructive plaques erode, develop localized thrombus, and produce myocardial infarction. This mechanism, plaque erosion rather than plaque rupture, is the dominant pathology in younger women’s acute coronary events. A 40 percent stenosis does not appear on the report as a problem. In women under 55 presenting with acute MI, autopsy and OCT (optical coherence tomography) data show plaque erosion as the underlying mechanism in the majority of cases, far more frequently than in older men where plaque rupture predominates.

Spontaneous coronary artery dissection. SCAD, in its milder presentations, produces subtle wall irregularity that standard angiography reads as a minor haziness rather than a clear dissection pattern. OCT performed during catheterization identifies intramural hematomas and false lumen formation invisible on surface angiographic imaging. SCAD is responsible for approximately 25 to 35 percent of acute MIs in women under 50 in referral center series.

The unifying point: the angiogram is designed to answer one question. Is there obstructive plaque above 50 percent in the large coronary arteries? It answers that question accurately. It was not designed to answer why a woman with typical ischemic symptoms is having chest pain, and it cannot answer that question alone. 5 / Solid

What the Evidence Shows

The clinical entity for ongoing ischemic-pattern chest pain with non-obstructive angiography has a name: ANOCA, Angina with Non-Obstructive Coronary Arteries. The term was formalized by the European Society of Cardiology working group on coronary pathophysiology, distinguishing it from MINOCA (the acute MI counterpart) and placing it within a structured diagnostic framework that requires further investigation rather than reassurance and discharge.

ANOCA is not one disease. It is a clinical presentation with multiple possible causes: microvascular coronary dysfunction (present in approximately 50 to 60 percent of ANOCA patients when coronary physiology testing is performed), coronary vasospasm (epicardial or microvascular, approximately 20 to 30 percent), non-obstructive atherosclerosis with functional significance below the 50 percent threshold, or combinations of the above. The CorMicA trial, published in the Journal of the American College of Cardiology in 2018 by Berry and colleagues, randomized 151 ANOCA patients to standard care versus coronary function testing with stratified treatment. In the coronary function testing group, a specific diagnosis was identified in 74 percent of patients, compared to 11 percent who received standard care. At 12 months, angina frequency and quality of life were significantly improved in the group that received diagnosis-directed treatment. The benefit of identifying the specific mechanism was substantial and measurable.

ANOCA patients are approximately 2 to 1 female. The sex disparity reflects two converging factors: the disproportionate burden of microvascular coronary dysfunction in women, and the systematic underperformance of coronary physiology testing in female patients in the United States. 5 / Solid

The Women’s Ischemia Syndrome Evaluation (WISE) study, the largest prospective study specifically designed to characterize coronary disease in women presenting with chest pain, enrolled 936 women referred for coronary angiography. At five-year follow-up, women with non-obstructive coronary arteries who had impaired coronary flow reserve on physiological testing had cardiovascular event rates approximately double those of asymptomatic women, and significantly higher rates of cardiac hospitalization and impaired quality of life than women with normal microvascular function. The WISE investigators, led by Merz and Pepine, established that MCD in women is not a benign functional diagnosis. It predicts events. It requires treatment.

The prognosis data from WISE and subsequent registry series is consistent: ANOCA is not a diagnosis of exclusion followed by reassurance. It is a starting point for further evaluation. Women with ongoing symptoms and a non-obstructive angiogram have approximately twice the five-year rate of major adverse cardiovascular events compared to age-matched women without cardiac symptoms.

The Physiology of Microvascular Coronary Dysfunction

Microvascular coronary dysfunction (MCD) is impaired function of the coronary arterioles that distribute blood into the myocardium at the capillary level. Normal coronary physiology produces a predictable response to increased demand: as the myocardium’s oxygen requirement increases with exercise, emotional stress, or elevated heart rate, the microvasculature dilates to increase flow proportionally. The ratio of maximal flow to resting flow is the coronary flow reserve (CFR). Normal CFR exceeds 2.5. Impaired CFR falls below 2.0. Values between 2.0 and 2.5 represent intermediate impairment.

In women with MCD, the microvasculature fails to dilate normally. The mechanism involves two overlapping pathways. The first is endothelial dysfunction: the endothelial cells lining the arterioles fail to produce adequate nitric oxide in response to increased shear stress, impairing the dilation signal. The second is structural abnormality: smooth muscle hypertrophy, adventitial fibrosis, and microvascular rarefaction (reduced vessel density per unit myocardium) that compounds the functional impairment. The myocardium receives insufficient blood flow for the level of demand. This is real ischemia, with demonstrable lactate production, ST-segment depression, and wall motion abnormality on imaging.

The sex-specific biology is specific and consequential. Women have longer coronary microvascular pathways proportional to body size. Estrogen maintains endothelial nitric oxide synthase activity in the microvasculature, and estrogen withdrawal at menopause directly impairs this mechanism. In the WISE cohort, the prevalence of impaired CFR increased substantially in postmenopausal women relative to premenopausal women, even after adjusting for age and traditional risk factors. The microvascular consequences of estrogen decline begin in the perimenopause years and accumulate. MCD is predominantly a postmenopausal women’s disease, though it occurs across age groups and has been documented in women in their 30s, particularly those with inflammatory conditions, autoimmune disorders, or PCOS. 5 / Solid

Inflammation compounds the vascular biology. High-sensitivity CRP above 2.0 mg/L correlates with impaired CFR independently of traditional risk factors. Women with elevated inflammatory markers are more likely to have MCD on coronary physiology testing. The connection is biologically plausible: systemic inflammation impairs endothelial function through TNF-alpha and IL-6 pathways that reduce nitric oxide bioavailability. A woman with elevated hs-CRP, normal standard lipid panel, and ongoing chest pain has a coherent physiological pathway that explains her symptoms even before a coronary angiogram is performed.

Coronary Vasospasm: The Test That Requires Provocation

Coronary vasospasm is episodic focal constriction of a coronary artery that significantly restricts blood flow. The classic presentation is rest pain, often nocturnal or in the early morning, associated with ST elevation or depression on ECG during the episode, that resolves spontaneously. If the patient undergoes angiography when she is not in active spasm, the artery looks completely normal. The diagnosis requires either capturing an episode on continuous ECG monitoring or performing provocative testing during catheterization. 5 / Solid

Intracoronary acetylcholine provocation testing is the clinical standard for diagnosing coronary vasospasm. Acetylcholine is injected into the coronary artery during catheterization. In patients with vasospasm, this triggers a controlled, reversible spasm detectable on catheterization images and on the ECG tracing, establishing the diagnosis definitively. The test adds 20 to 30 minutes to a diagnostic catheterization. It is standard of care in Japan and across much of Europe. It is substantially underperformed in the United States, where the majority of catheterization laboratories do not perform it routinely, and where its underuse disproportionately affects women.

Approximately 20 to 30 percent of ANOCA patients demonstrate coronary vasospasm on provocative testing. The treatment is specific: calcium channel blockers and nitrates rather than aspirin and statins, with avoidance of vasospastic triggers including cold exposure, emotional stress, and smoking. A woman with vasospastic angina who has not been diagnosed will receive incorrect therapy or no therapy. She will continue having symptoms that were diagnosable and treatable.

Microvascular vasospasm, spasm in the small arterioles rather than the epicardial coronary arteries, can also be diagnosed with acetylcholine provocation and represents a distinct subset of MCD with specific therapeutic implications.

Cardiologist's Note

The clinical failure in ANOCA is not performing the angiogram. The angiogram is correct and necessary. The clinical failure is stopping at the angiogram.

A woman with two years of exertional chest pain, a normal angiogram, and a discharge note reading “negative workup, reassured” has not had a negative workup. She has had a negative obstructive plaque workup. The workup for why she is having chest pain has not begun. The next step is coronary physiology assessment, provocative testing for vasospasm, and cardiac MRI with stress perfusion, not reassurance and discharge.

The pattern I see repeatedly in referral practice: a woman who has had one or two angiograms at outside institutions, both read as normal, who has been told her symptoms are anxiety or atypical, who has been managing symptoms for years without a diagnosis. When we perform coronary flow reserve measurement and acetylcholine provocation during catheterization, we find a specific mechanism in the majority of these patients. We then have a diagnosis. We then have a treatment target. The symptoms that persisted for years become manageable in months.

Physiological testing during catheterization is the standard of care for ANOCA in current European Society of Cardiology guidelines. The American Heart Association has issued a scientific statement explicitly recommending comprehensive coronary function testing for women with ischemic symptoms and non-obstructive coronary arteries. The statement exists because the testing is not being done. Knowing these recommendations by name allows patients to name them in the clinical encounter.

The Diagnostic Workup After a Normal Angiogram

The pathway for ongoing chest pain after a non-obstructive angiogram is structured, not speculative.

Coronary physiology testing during catheterization. If catheterization has been performed, intracoronary pressure and flow measurements evaluate whether the microvasculature is functioning normally. The indices are coronary flow reserve (CFR), fractional flow reserve (FFR), and index of microvascular resistance (IMR). These measurements add 20 to 30 minutes to the catheterization. CFR below 2.0 establishes impaired microvascular function. IMR above 25 identifies microvascular resistance as the mechanism. These measurements transform an angiogram that said “no obstruction” into a catheterization that says “no obstruction, with impaired coronary flow reserve, consistent with MCD.” The latter is a diagnosis with a treatment pathway.

Cardiac MRI with stress perfusion. CMR with adenosine or regadenoson stress identifies stress-induced perfusion abnormalities in the absence of obstructive disease, directly imaging the downstream consequence of microvascular dysfunction. Subendocardial perfusion defects on stress CMR are present in approximately 30 to 40 percent of women with ANOCA and impaired CFR. CMR also evaluates for myocarditis, prior MI by late gadolinium enhancement, and Takotsubo cardiomyopathy morphology. It does not require catheterization and provides functional information complementary to coronary anatomy.

Provocative vasospasm testing. If vasospasm is in the differential, intracoronary acetylcholine provocation during catheterization is the gold standard. Rest pain, nocturnal symptoms, early morning symptoms, ST elevation on ECGs captured during chest pain, smoking history, and absence of metabolic syndrome all raise the pretest probability of vasospastic angina.

OCT during catheterization. If the angiogram showed any vessel irregularity, haziness, or slow flow, and if the patient has demographic features raising concern for SCAD, such as women under 55, peripartum presentation, connective tissue disorder history, or fibromuscular dysplasia, OCT during catheterization identifies SCAD patterns and plaque erosion morphology that standard angiography cannot resolve.

What to Do This Week

If you have been told your angiogram was normal and you continue having chest pain, ask specifically: “Has coronary flow reserve or microvascular resistance been measured?” If the answer is no, the physiological workup has not been completed.
Request a referral to a center that performs coronary function testing routinely during catheterization. Not all catheterization laboratories do this. The CorMicA trial protocol, the ESC ANOCA guideline pathway, and the AHA scientific statement on ANOCA in women are three named documents you can reference by name in the clinical encounter.
Ask whether cardiac MRI with stress perfusion has been considered. CMR provides non-invasive physiological information that complements the anatomic data from angiography.
If your symptoms have a rest pattern, nocturnal pattern, or if any ECG captured during a pain episode showed ST changes, raise coronary vasospasm and ask whether provocative testing has been considered.
Ask for an explicit ANOCA diagnosis documentation if it applies, and request the conversation about what further evaluation is indicated. “Negative workup” is not an accurate characterization of a workup that stopped at the angiogram.

The angiogram reported what it was designed to report. It was correct. It was also incomplete. The test that answered “is there a major blockage” did not answer “why is she having chest pain.” Those are not the same question. The additional tests that answer the second question exist, are validated, and are increasingly recognized as standard practice. A normal angiogram is the beginning of the diagnostic process, not its conclusion.

For the acute MI version of this presentation: MINOCA: The Heart Attack With Normal Arteries.

For the arterial tear that a standard angiogram can miss: SCAD: The Heart Attack That Tears the Artery Wall.

For why cardiac symptoms in women are systematically dismissed: Why Women’s Heart Disease Gets Dismissed.

Find out which signals are active in your own pattern.

Take the Women's Signal Check

Did this land?

The conversation

Join the men working through this in the open.